The Board of Directors of Aurobindo Pharma Limited has sanctioned a Scheme of Amalgamation involving two wholly owned subsidiaries: Auro Vaccines Private Limited and Curateq Biologics Private Limited. This internal restructuring aims to streamline operations, reduce regulatory compliance burdens, and optimize overall group costs. The transaction is an amalgamation between two entities already under the parent company’s control, meaning no consideration will be paid.
Internal Restructuring Approved by Board
Aurobindo Pharma Limited announced on February 9, 2026, that its Board of Directors has approved a proposal to file a Scheme of Amalgamation for the merger of two wholly owned subsidiaries. The approval was granted following a Board meeting that commenced at 4:30 p.m. and concluded at 6:30 p.m.
Details of the Amalgamation
The proposed merger involves the amalgamation of:
- Transferor Company: Auro Vaccines Private Limited (a wholly owned step-down subsidiary, incorporated in November 2021, and a subsidiary of Curateq).
- Transferee Company: Curateq Biologics Private Limited (a wholly owned subsidiary, incorporated in April 2020).
Both entities are involved in the Manufacturing and marketing of pharmaceutical products.
Financial Snapshot (FY ended March 31, 2025)
The turnover figures for the last financial year highlight the relative scale of the merging entities:
- Curateq: INR 84.8 million
- Auro Vaccines: Nil
Rationale and Consideration
The primary rationale for this merger is the consolidation of these entities, which is expected to result in reducing the number of entities in the group, optimization of operational costs, and reduction in regulatory compliances.
Crucially, no consideration (cash or share exchange ratio) will be paid, as the merger is strictly between two wholly owned subsidiaries of Aurobindo Pharma Limited.
Related Party and Shareholding Implications
The transaction is between two wholly owned subsidiaries; therefore, provisions related to related party transactions under relevant regulations are not applicable. Furthermore, since Aurobindo Pharma Limited is not a direct party to the Scheme of Amalgamation, the shareholding pattern of the listed entity remains unchanged.
Source: BSE
